Predictive Oncology Inc.
POAI
$0.9355
-$0.013-1.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -4.09% | -22.96% | 9.37% | 33.21% | 14.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.09% | -22.96% | 9.37% | 33.21% | 14.66% |
| Cost of Revenue | 33.62% | 46.67% | 25.60% | 33.17% | 22.67% |
| Gross Profit | -25.20% | -52.81% | 0.67% | 33.23% | 10.64% |
| SG&A Expenses | -10.18% | -14.81% | -15.61% | -7.51% | -13.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.34% | -12.79% | -14.32% | -6.26% | -12.07% |
| Operating Income | 8.90% | 11.55% | 16.64% | 9.95% | 14.70% |
| Income Before Tax | 9.95% | 29.62% | 31.99% | 46.17% | 49.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.95% | 29.62% | 31.99% | 46.17% | 49.16% |
| Earnings from Discontinued Operations | 2.04% | -211.85% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.44% | 24.18% | 27.34% | 42.68% | 45.67% |
| EBIT | 8.90% | 11.55% | 16.64% | 9.95% | 14.70% |
| EBITDA | 7.64% | 8.57% | 14.10% | 5.96% | 11.11% |
| EPS Basic | 27.41% | 34.06% | 31.29% | 46.21% | 49.98% |
| Normalized Basic EPS | 25.75% | 20.98% | 20.52% | 12.62% | 20.45% |
| EPS Diluted | 27.36% | 34.02% | 31.32% | 46.21% | 50.01% |
| Normalized Diluted EPS | 25.75% | 20.98% | 20.52% | 12.62% | 20.45% |
| Average Basic Shares Outstanding | 35.75% | 20.43% | 6.33% | 4.80% | 8.97% |
| Average Diluted Shares Outstanding | 35.75% | 20.43% | 6.33% | 4.80% | 8.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |